When did Silexion Therapeutics Corp go public?

Silexion Therapeutics Corp completed its IPO on May 29, 2026 on Nasdaq under the ticker SLXN and now trades publicly.

Can I buy Silexion Therapeutics Corp stock?

Yes — Silexion Therapeutics Corp is publicly traded on Nasdaq as SLXN. You can follow its live price, valuation and post-IPO performance above.

What is Silexion Therapeutics Corp's valuation?

Silexion Therapeutics Corp's most recent valuation tracked here is $2.51M, derived from live market prices.

All companies

Silexion Therapeutics Corp

SLXN

PublicArchived

Public / ArchivedUnited States(Nasdaq)Best valuation $2.51M1 market

Public listing

Listed· Nasdaq· Listing market: United States

Listing date

May 29, 2026

Offer price

Not available

Shares offered

Not available

Offering proceeds

Not available

Sources: sec-harvest, sec-edgar, nasdaq

IPO Calendar · NasdaqIPO

SLXN

Price

$0.4355

24h

+14.61%

Valuation

$2.51M

24h volume

$12.11M

Type

IPO

Trade Silexion Therapeutics Corp

Now trading publicly. Buy via a broker — opens in a new tab.

Trade on IPO Calendar

IPO Calendar · updated 2h ago

Silexion Therapeutics Corp IPO public float & lock-up

Public float and locked shares extracted from Silexion Therapeutics Corp's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.

424B4Aug 13, 2026

Total shares (FD)

3.38M

Public float

—

Locked

—

IPO raise

—

Next unlock

—

Needs review: Could not extract a detailed lock-up release schedule.

Financials

Unprofitable

From SEC filings, latest FY ending Dec 31, 2025 · CIK 0002022416.

Revenue

—

Net income

-$11.91M

Gross margin

—

Cash

$5.99M

Metric	2025	2024	2023
Operating income	-$11.63M	-$12.57M	-$4.68M
Net income	-$11.91M	-$16.52M	-$5.11M
R&D expense	$7.14M	$5.82M	$3.71M
Cash & equivalents	$5.99M	$1.19M	$4.6M
Total assets	$7.22M	$2.86M	$5.26M
Total liabilities	$4.61M	$6.85M	$2.26M
Shareholders' equity	$2.6M	-$3.99M	-$15.48M

SEC IPO filings

Final prospectus

EDGAR filings resolved from SLXN / CIK 0002022416.

424B4424B4

Aug 13, 2026Final prospectus0001178913-26-004116

EFFECTxslEFFECTX01/primary_doc.xml

Aug 11, 2026Effective9999999995-26-002627

S-1/AS-1/A

Aug 10, 2026Amended0001178913-26-004003

S-1S-1

Aug 7, 2026Filed0001178913-26-003961

EFFECTxslEFFECTX01/primary_doc.xml

Jun 18, 2026Effective9999999995-26-002070

424B3424B3

Jun 18, 2026Final prospectus0001178913-26-003253

EFFECTxslEFFECTX01/primary_doc.xml

May 11, 2026Effective9999999995-26-001566

EFFECTxslEFFECTX01/primary_doc.xml

May 11, 2026Effective9999999995-26-001565

DRSfilename1.htm

Mar 17, 2026Confidential draft0001178913-26-000955

EFFECTxslEFFECTX01/primary_doc.xml

Sep 30, 2025Effective9999999995-25-003257

CORRESPfilename1.htm

Sep 30, 2025SEC correspondence0001178913-25-003421

UPLOADfilename1.pdf

Sep 29, 2025SEC correspondence0000000000-25-010616

Silexion Therapeutics Corp IPO — frequently asked questions

When did Silexion Therapeutics Corp go public?: Silexion Therapeutics Corp completed its IPO on May 29, 2026 on Nasdaq under the ticker SLXN and now trades publicly.
Can I buy Silexion Therapeutics Corp stock?: Yes — Silexion Therapeutics Corp is publicly traded on Nasdaq as SLXN. You can follow its live price, valuation and post-IPO performance above.
What is Silexion Therapeutics Corp's valuation?: Silexion Therapeutics Corp's most recent valuation tracked here is $2.51M, derived from live market prices.